Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 8, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00744-17
Keywords
HIV-2; MK-8591; 4 '-ethynyl-2-fluoro-2 '-deoxyadenosine; EFdA; NRTI; antiretroviral therapy; drug resistance; HIV-1
Categories
Funding
- National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) [1R01-AI120765, 2R01-AI060466]
- UW Center for AIDS Research (CFAR, an NIH) [P30 AI027757]
- UW Royalty Research Fund [A92723]
- U.S. National Institutes of Health
- University of Washington
- Bill and Melinda Gates Foundation
- Gilead Sciences
- Alere Technologies
- Merck Co.
- Janssen Pharmaceutica
- Cerus Corporation
- Abbott Molecular Diagnostics
- Mary Gates Endowment
- NIH/NIAID
- France Recherche Nord & Sud Sida-hiv Hepatites (ANRS)
Ask authors/readers for more resources
There is a pressing need to identify more effective antiretroviral drugs for HIV-2 treatment. Here, we show that the investigational compound MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine [EFdA]) is highly active against group A and B isolates of HIV-2; 50% effective concentrations [EC50] for HIV-2 were, on average, 4.8-fold lower than those observed for HIV-1. MK-8591 also retains potent activity against multinucleoside-resistant HIV-2 mutants (EC50 <= 11 nM). These data suggest that MK-8591 may have antiviral activity in HIV-2-infected individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
